Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved
Alnylam Pharmaceuticals, Inc. (ALNY) shares rose 0.2% to $237.10 as of August 29, 2026, a slight gain from the prior close of $236.56. BestStocks flagged the session as a major change for ALNY. The move is tied to price move up. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ALNY climbed 0.2% to $237.10
ALNY rose 0.2% in its latest session, moving from $236.56 to $237.10.
What it means for Alnylam Pharmaceuticals, Inc. investors
For Alnylam Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 0.2% session move. Weighing against that: Alnylam Pharmaceuticals plummeted 27.66% to $207.34 following an earnings report and material event filing (8-K) released today; Alnylam Pharmaceuticals, Inc. (ALNY) moved -5.54% from $283.15 to $267.47 on 2026-07-17. Wall Street's consensus price target sits at $344.83, implying +45.4% upside from $237.10. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 61 days out, the next report is the most likely near-term test of the move.
ALNY price reaction
ALNY last traded at $237.10, up $0.54 (+0.23%) from the previous close of $236.56. The session traded on 1.2× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $205.48 and $286.62, and it currently sits about 39% of the way up that band.
Bullish and bearish analyst opinions on Alnylam Pharmaceuticals, Inc. (ALNY)
The consensus analyst price target on Alnylam Pharmaceuticals, Inc. (ALNY) is $344.83, 45.4% above the recent $237.10. Over the past 90 days analysts logged 1 upgrade, 21 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ALNY line up.
The bullish case
- Wall Street's consensus price target of $344.83 implies +45.4% upside from $237.10.
- The Street's most bullish target is $455.00 (+91.9%).
- 1 analyst upgrade in the past 90 days, most recently Raymond James to Strong Buy (2026-08-03).
- Material positive event.
- Positive 0.2% session move.
The bearish case
- The most bearish analyst target is $230.00 (-3.0%).
- Alnylam Pharmaceuticals plummeted 27.66% to $207.34 following an earnings report and material event filing (8-K) released today.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 28, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ALNY
Frequently asked questions about ALNY
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?
ALNY rose 0.2% to $237.10. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ALNY stock rise?
ALNY gained 0.23% ($0.54) versus the prior close of $236.56, last trading at $237.10 on 1.2× average volume.
When is Alnylam Pharmaceuticals, Inc.'s next earnings date?
ALNY's next earnings report is estimated for 2026-10-29 — about 61 days away.
What is the analyst price target for ALNY?
The consensus analyst price target for ALNY is $344.83, about 45.4% above the current $237.10. Over the past 90 days, analysts recorded 1 upgrade, 21 maintains, and 0 downgrades.
How BestStocks tracks ALNY
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for ALNY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.